Home Featured Page 18

Featured

Latest

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

The Hidden History of Psychedelics in Australia

Patients, Practitioners, Researchers and Public Submit Comments Ahead of FDA Advisory...

Embracing the Mystery: Making Psychedelic Literature Engaging

What to Expect: FDA Advisory Committee Set to Review MDMA-Assisted Therapy...

Pα+ Psychedelic Patent Analysis: April 2024

Breaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?

Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares...

Depth Psychology, Archetypal Energies, and How Psychedelics Reveal the Soul

1...171819...277 Page 18 of 277

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Long COVID and Psychedelics

The Hidden History of Psychedelics in Australia

Patients, Practitioners, Researchers and Public Submit Comments Ahead of FDA Advisory...

Embracing the Mystery: Making Psychedelic Literature Engaging

What to Expect: FDA Advisory Committee Set to Review MDMA-Assisted Therapy...

The Economics of Psychedelics

Pα+ Psychedelic Patent Analysis: April 2024

Breaking Through Bureaucracy: Can D.C. Embrace Evidence-Based Drug Policy?

Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares...

Depth Psychology, Archetypal Energies, and How Psychedelics Reveal the Soul

EDITOR PICKS

Psychedelic Alpha’s Top 11 Stories from 2024

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY